Casdin Capital’s Editas Medicine EDIT Stock Holding History

Casdin Capital’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.44M	Buy	+445,000	New	+$1.3M	0.07%	38
2019 Q4	–	Sell	-415,000	Closed	-$9.44M	–	33
2019 Q3	$9.44M	Sell	415,000 -65,000	-14%	-$1.61M	0.98%	27
2019 Q2	$11.9M	Hold	480,000	–	–	1.11%	24
2019 Q1	$11.7M	Hold	480,000	–	–	1.29%	21
2018 Q4	$10.9M	Buy	480,000 +20,000	+4%	+$544K	1.87%	22
2018 Q3	$14.6M	Buy	460,000 +281,667	+158%	+$9.1M	1.78%	21
2018 Q2	$6.39M	Buy	178,333 +45,000	+34%	+$1.59M	0.89%	25
2018 Q1	$4.42M	Hold	133,333	–	–	0.78%	25
2017 Q4	$4.1M	Hold	133,333	–	–	1%	21
2017 Q3	$3.2M	Hold	133,333	–	–	0.9%	24
2017 Q2	$2.24M	Hold	133,333	–	–	0.83%	30
2017 Q1	$2.98M	Buy	133,333 +68,333	+105%	+$1.42M	1.76%	21
2016 Q4	$1.05M	Sell	65,000 -20,470	-24%	-$311K	0.87%	24
2016 Q3	$1.15M	Buy	+85,470	New	+$1.75M	0.93%	25
2016 Q2	–	Sell	-85,470	Closed	-$2.95M	–	29
2016 Q1	$2.95M	Buy	+85,470	New	+$2.25M	3.39%	14

Other funds holding EDIT

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Casdin Capital's EDIT Position: Q2 2026 in Review

Casdin Capital opened a new position in Editas Medicine (EDIT) in Q2 2026: 445,000 shares worth $1.44M. The stake represents 0.07% of the portfolio and ranks #38 among its holdings. This is a return to the name: Casdin Capital previously reported a position in EDIT as recently as Q3 2019.

Casdin Capital first reported a position in EDIT in Q1 2016 and has held it in 15 quarters since. The position peaked at $14.6M in Q3 2018. 216 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

Casdin Capital held 445,000 shares of Editas Medicine worth $1.44M as of Q2 2026.
Editas Medicine was a new Casdin Capital position in Q2 2026.
Editas Medicine made up 0.07% of Casdin Capital's portfolio in Q2 2026, its #38 holding.
Casdin Capital first reported a position in Editas Medicine in Q1 2016 and has held it in 15 quarters since.
Casdin Capital's Editas Medicine position peaked at $14.6M in Q3 2018.
216 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.